Risk of myocardial ischaemia and beta-adrenoceptor agonists

Modern therapy for both cardiovascular disease and obstructive lung disease involves diametrically opposed manipulations of the beta-adrenoceptor. Beta-agonists reduce airflow limitation and improve symptoms among patients with obstructive lung disease while beta-blockers reduce symptoms, recurrent myocardial ischaemia and all-cause mortality among patients with ischaemic heart disease. There is biological plausibility for beta-agonists leading to adverse cardiovascular outcomes, and observational trials have raised concern about the safety of beta-agonists among patients with cardiovascular disease. Although there are many potential causal and noncausal explanations for these observational findings, the implications from these studies are the same. Physicians should be careful when prescribing beta-agonists for patients at risk for ischaemic heart disease. Furthermore, careful consideration should be given to distinguish symptoms caused by cardiovascular versus respiratory aetiologies.

[1]  Michael J. Goodman,et al.  Contraindicated use of cisapride: impact of food and drug administration regulatory action. , 2000, JAMA.

[2]  B. Psaty,et al.  The Risk of Myocardial Infarction Associated with Inhaled β -Adrenoceptor Agonists , 2000 .

[3]  J. Woodcock,et al.  The safety of newly approved medicines: do recent market removals mean there is a problem? , 1999, JAMA.

[4]  M. Cazzola,et al.  Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. , 1998, Chest.

[5]  N. Dunn,et al.  Risk of non-fatal cardiac failure and ischaemic heart disease with long acting β2 agonists , 1998, Thorax.

[6]  B. Psaty,et al.  Time to act on drug safety. , 1998, JAMA.

[7]  Brian Lipworth,et al.  Association between β2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics , 1997, The Lancet.

[8]  M. Sears.  Bronchodilators and acute cardiac death. , 1997, American journal of respiratory and critical care medicine.

[9]  P. Barnes,et al.  Effect of short- and long-acting β2-adrenoceptor agonists on pulmonary β2-adrenoceptor expression in human lung , 1996 .

[10]  I. Hall.  Beta 2 adrenoceptor polymorphisms: are they clinically important? , 1996, Thorax.

[11]  I. Hall,et al.  Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. , 1995, American journal of respiratory cell and molecular biology.

[12]  J Crane,et al.  End of the New Zealand asthma mortality epidemic , 1995, The Lancet.

[13]  D. Romberger,et al.  Agonist-induced desensitization of beta-adrenoceptors of bovine bronchial epithelial cells. , 1993, Clinical science.

[14]  P. Barnes,et al.  Differential down-regulation of pulmonary β1- and β2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline , 1993 .

[15]  A. Buist,et al.  Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity? , 1993, The American review of respiratory disease.

[16]  A. Buist,et al.  Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. , 1992, JAMA.

[17]  E. Robin,et al.  Sudden cardiac death in bronchial asthma, and inhaled beta-adrenergic agonists. , 1992, Chest.

[18]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[19]  J Crane,et al.  Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. , 1991, Thorax.

[20]  I. Pavord,et al.  Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma , 1990, The Lancet.

[21]  B. Psaty,et al.  The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. , 1990, JAMA.

[22]  N. Pearce,et al.  Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. , 1990, Thorax.

[23]  N. Pearce,et al.  PRESCRIBED FENOTEROL AND DEATH FROM ASTHMA IN NEW ZEALAND, 1981-83; CASE-CONTROL STUDY , 1989, The Lancet.

[24]  J. Paterson,et al.  Adverse Reactions to β2-Agonist Bronchodilators , 1986 .

[25]  P. Corris,et al.  Nebulised salbutamol and angina. , 1982, British medical journal.

[26]  Bengt Bengtsso,et al.  Extrapulmonary effects of terbutaline during prolonged administration , 1982, Clinical pharmacology and therapeutics.

[27]  A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. , 1982, JAMA.

[28]  Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. , 1981, The New England journal of medicine.

[29]  D. Gordon.  Letter: Woodpecker's tongues. , 1976, Lancet.

[30]  A M Adelstein,et al.  Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. , 1969, Lancet.

[31]  M. Lockett.  DANGEROUS EFFECTS OF ISOPRENALINE IN MYOCARDIAL FAILURE. , 1965, Lancet.